Stockscreener 앱 받기
46.50
0.09%
-0.04
Gsk Plc Adr 주식(GSK)의 최신 뉴스
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies - GlobeNewswire Inc.
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? - Zacks Investment Research
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - GlobeNewswire Inc.
Form 13D/A Opera Limited For: 24 September By Investing.com - Investing.com UK
GSK (NYSE: GSK) board members are buying company stock - Stock Titan
Renalytix rises 7% as UBS holding grows and CEO buys shares - Yahoo Finance UK
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Australia
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Zacks Investment Research - גלובס
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? - TradingView
GSK stock holds steady as investors weigh recent earnings and dividend - ad-hoc-news.de
BNTX Stock Price, Quote & News - Syfe
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? - sahmcapital.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingGrowth Acceleration Report - careplusvn.com
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingEarnings Decline Risk - dars.gov.et
GSK (GSK) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Latest Session; Post-Earnings: Shares Move Lower 1.20% in Latest TradingOne-Time Gain Impact - www.dars.gov.et
Resilient GSK stock holds firm as FDA and Japan clear key drugs - ad-hoc-news.de
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - ad-hoc-news.de
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayProfit Cycle Analysis - careplusvn.com
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayRevenue Breakdown Analysis - dars.gov.et
GSK (GSK) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison on the Day; Price Move: Shares Fall 1.74% on the DayEarnings Power Value - dars.gov.et
GSK (GSK) Latest: Ends Higher by 2.35% at $52.35 at the Close; Market Levels: $49.73 and $54.97 Define the Nearby Reference Levels at the CloseVolume Weighted Price - careplusvn.com
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop - Morningstar
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added - TipRanks
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Weekly Recap: £1.9B savings target and Artemis-011 hits Phase III goal - TradingView
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan - TradingView
GSK reports $11.28 billion second quarter 2026 revenue - grafa.com
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals - Sahm
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK - TradingView
Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK: Glaxosmithkline plcADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Sahm
Free cash flow of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSK.CI - TradingView
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies - GlobeNewswire Inc.
Dorsey Wright & Associates Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK ends camlipixant programme after CALM-2 miss - grafa.com
Disappointing Data Prompts GSK to Drop Cough Drug Development - Sahm
American Kidney Fund Expands Kidney Health Coach Program with Educational Course on Lupus Nephritis - GlobeNewswire Inc.
GSKH ETF Profile: Dividends, Returns (AMEX:GSKH) - TradingView
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer - TradingView
GSK (NYSE: GSK) leaders boost share exposure via dividend reinvestment - stocktitan.net
GSK reports Jemperli rectal cancer trial results - grafa.com
0.40%
3.33%
자본화:
|
볼륨(24시간):